The Latest Breaking News from Alkermes

Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter.

Alkermes is the IBD Stock Of The Day after strong first-quarter sales of its new bipolar treatment, Lybalvi, led Alkermes stock to break out.

Thanks to the global COVID-19 vaccination drive and inelastic demand for healthcare, biotechnology stocks have been outperforming the broader markets so far this year. Because this trend will likely continue, we think investing in popular biotech stocks Regeneron Pharmaceuticals (REGN), Exelixis (EXEL), Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Incyte Corp.…

Upgrades

Alkermes plc (NASDAQ:ALKS) commenced binding arbitration proceedings regarding two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson (NYSE:JNJ).  Under these agreements, Janssen received access and rights to Alkermes' small particle pharmaceutical compound technology, known as NanoCrystal Technology, enabling several products.  Janssen partially terminated the agreements in the U.S., effective as of…

According to Benzinga Pro, during Q4, Alkermes (NASDAQ:ALKS) earned $873.00 thousand, a 103.01% increase from the preceding quarter. Alkermes also posted a total of $324.46 million in sales, a 10.31% increase since Q3.

Alkermes plc's (NASDAQ: ALKS) 

  Alkermes (NASDAQ:ALKS) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will report an earnings per share (EPS) of $0.11.